Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 12/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 11/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 3/20 | 1.00 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.47 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
| ▸ | SGK1 | O00141 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | BLK | P51451 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29432586 | 1.00 | MAPK10 (1.00) | MAPK10MAPK9MAPK8MKNK1MKNK2 | |
| SCHEMBL21067982 | 1.00 | MAPK10 (1.00) | MAPK10MAPK9MAPK8MKNK1MKNK2 | |
| SCHEMBL4022963 | 0.92 | MAPK10 (0.84) | MAPK10MAPK9MAPK8MKNK1MKNK2 | |
| SCHEMBL4022971 | 0.91 | MAPK10 (0.84) | MAPK10MAPK9MAPK8MKNK1MKNK2 | |
| SCHEMBL2887536 | 0.86 | MAPK10 (0.76) | MAPK10MAPK9MAPK8MKNK1MKNK2 | |
| SCHEMBL2884761 | 0.86 | MAPK10 (0.75) | MAPK10MAPK9MAPK8MKNK1MKNK2 | |
| SCHEMBL2881373 | 0.86 | MAPK10 (0.75) | MAPK10MAPK9MAPK8NPC1RAB9A | |
| SCHEMBL2879038 | 0.86 | MAPK10 (0.75) | MAPK10MAPK9MAPK8NPC1RAB9A | |
| SCHEMBL4023159 | 0.86 | MAPK10 (0.75) | MAPK10MAPK9MAPK8NPC1RAB9A | |
| SCHEMBL2886187 | 0.86 | MAPK10 (0.75) | MAPK10MAPK9MAPK8MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220061311-A1 | COMPOSITIONS AND METHODS FOR REDUCING CRYOPRESERVATION TOXICITY | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-03-03 | — | — | US | claimed |
| US-20140107116-A1 | BENZOTHIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK SERONO SA (CH) | 2014-04-17 | — | — | US | claimed |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-24 | — | — | US | claimed |
| US-20100291069-A1 | METHODS OF TREATING A DIABETIC EMBRYOPATHY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-11-18 | — | — | US | claimed |
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2009-07-09 | — | — | US | claimed |
| US-7470686-B2 | Method of inhibiting the expression and/or the activity of JNK | LABORATOIRES SERONO SA (CH) | 2008-12-30 | — | — | US | claimed |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-02-14 | — | — | US | claimed |
| EP-1696909-B1 | BENZOTHIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | SERONO LAB (CH) | 2007-11-14 | — | — | EP | claimed |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-11-08 | — | — | US | claimed |
| US-7259162-B2 | Benzazole derivatives and their use as JNK modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-21 | — | — | US | claimed |
| EP-1240164-B1 | BENZAZOLE DERIVATIVES AND THEIR USE AS JNK MODULATORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-11-12 | — | — | EP | claimed |
| US-20030162794-A1 | Benzazole derivatives and their use as jnk modulators | MERCK SERONO SA (CH) | 2003-08-28 | — | — | US | claimed |
| EP-1110957-A1 | Benzazole derivatives and their use as JNK modulators | Applied Research Systems ARS Holding N.V. (AN) | 2001-06-27 | — | — | EP | claimed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| CN-118318033-A | Cell aggregate comprising pituitary hormone-producing cells and method for producing the same | 住友制药株式会社 | 2024-07-09 | — | — | CN | disclosed |
| EP-1240164-B1 | BENZAZOLE DERIVATIVES AND THEIR USE AS JNK MODULATORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-11-12 | — | — | EP | disclosed |
| US-20030162794-A1 | Benzazole derivatives and their use as jnk modulators | MERCK SERONO SA (CH) | 2003-08-28 | — | — | US | disclosed |
| WO-2003047570-A1 | BENZAZOLE DERIVATIVES FOR THE TREATMENT OF SCLERODERMA | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2003-06-12 | — | — | WO | disclosed |
| EP-1110957-A1 | Benzazole derivatives and their use as JNK modulators | Applied Research Systems ARS Holding N.V. (AN) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162794-A1 | Benzazole derivatives and their use as jnk modulators | MAPK1, MAPK3, MAPKAPK2 | MAPK10 46/4885MAPK9 24/4885MAPK8 10/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | MAPK10 2310/4885MAPK9 2569/4885MAPK8 4258/4885 |
| US-20220061311-A1 | COMPOSITIONS AND METHODS FOR REDUCING CRYOPRESERVATION TOXICITY | IQGAP1, UGGT1, FLNA | MAPK10 748/4885MAPK9 288/4885MAPK8 1890/4885 |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | MAP3K20, MAPK3, MAPK10 | MAPK10 3/4885MAPK9 28/4885MAPK8 12/4885 |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | LCK, MAPKAPK2, MAP3K20 | MAPK10 40/4885MAPK9 36/4885MAPK8 47/4885 |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | MAPK10 40/4885MAPK9 49/4885MAPK8 32/4885 |
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | MAPKAPK2, MAP3K20, MAP3K6 | MAPK10 26/4885MAPK9 35/4885MAPK8 56/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | MAPK10 2310/4885MAPK9 2569/4885MAPK8 4258/4885 |
| US-20140107116-A1 | BENZOTHIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | GPR119, GLS2, GLS | MAPK10 3544/4885MAPK9 4459/4885MAPK8 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.